单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）治疗癌症的临床与基础研究进展
英文原题：Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer.
查看英文原题
Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
恶性肿瘤对人类健康构成重大威胁。在现有的多种治疗策略中，癌症免疫治疗——包括过继性细胞转移（ACT）和免疫检查点阻断治疗——已成为继手术切除、放疗、化疗和分子靶向治疗之后一种特别有前景的方法。这种治疗形式能引发显著的抗原特异性免疫反应，增强或恢复抗肿瘤免疫，从而促进对肿瘤细胞的控制和破坏，并在多种癌症中产生持久应答，可导致肿瘤病灶的清除和复发的预防。TIL（肿瘤浸润淋巴细胞）（TILs）是ACT的一个亚群，其特征是异质性，存在于肿瘤组织中，在介导宿主针对肿瘤的抗原特异性免疫反应中发挥关键作用。本综述旨在探讨TILs生物学、其预后意义及其在治疗背景下的预测价值方面的最新进展。
展开英文摘要原文
Malignant tumors represent a significant threat to human health. Among the various therapeutic strategies available, cancer immunotherapy-encompassing adoptive cell transfer (ACT) and immune checkpoint blockade therapy-has emerged as a particularly promising approach following surgical resection, radiotherapy, chemotherapy, and molecular targeted therapies. This form of treatment elicits substantial antigen-specific immune responses, enhances or restores anti-tumor immunity, thereby facilitating the control and destruction of tumor cells, and yielding durable responses across a range of cancers, which can lead to the eradication of tumor lesions and the prevention of recurrence.
Tumor-infiltrating lymphocytes (TILs), a subset of ACT, are characterized by their heterogeneity and are found within tumor tissues, where they play a crucial role in mediating host antigen-specific immune responses against tumors. This review aims to explore recent advancements in the understanding of TILs biology, their prognostic implications, and their predictive value in therapeutic contexts.
论文信息
- 作者
- Hu J、Jin M、Feng W、Nassif-Rausseo B、Reuben A、Ma C、Lizee G、Li F
- 单位
- Core Laboratory, Tianjin Beichen Hospital, Tianjin 300400, China.China
- 文献类型
- 综述
- 期刊
- Vaccines2025 May 14
- 原文标识
- PubMed 40432130 · DOI 10.3390/vaccines13050521
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →